University of Kuopio in Finland Uses PerkinElmer FT-IR Imaging Technology
As A New Way to Study Cartilage Degeneration
BOSTON, MA -- August 26, 2004 -- PerkinElmer, Inc. (NYSE: PKI), a leading provider of drug discovery, life science research, and analytical solutions, today announced that its Spectrum Spotlight FT-IR Imaging System is being used in research into musculoskeletal diseases at the Biophysics of Bone and Cartilage (BBC) group at the University of Kuopio in Finland. The group announced details of new research at the Orthopaedic Research Society meetings in New Orleans and San Francisco, showing that FT-IR imaging is an important new tool for discerning different grades of cartilage degeneration.
Fourier-Transform Infrared (FT-IR) imaging is an analytical technique for determining the microscale molecular composition of a wide range of materials. The technique is currently being used in many industrial application areas including manufacturing and new product development, where it provides vital information about defects, impurities and composition, reducing costs and decreasing time-to-market. Recently, researchers have begun to test how this imaging technology can be applied in medicine and in the study of disease.
The University of Kuopio has determined that PerkinElmer's SpectrumTM Spotlight system can accurately and quickly detect different grades of cartilage degeneration in human, bovine and porcine samples. Musculoskeletal diseases include osteoarthritis, osteoporosis, Carpal Tunnel Syndrome and other diseases involving the degeneration of bone, cartilage and muscle tissue. Until now, it was not possible to rapidly measure infrared images over wide areas at high sensitivity, but initial studies show that the Spectrum Spotlight can accurately provide images of degeneration within minutes.
"The Spotlight imaging system now allows us to rapidly measure minute changes in chemical composition, such as collagen content, which was impossible with traditional FT-IR approaches," explained Dr. Jarno Rieppo of the Department of Anatomy at the University of Kuopio. "This advancement in FT-IR imaging means we have a new technique in the study of cartilage degeneration that allows us to design experiment protocols that were not possible before."
"The BBC group's use of our Spectrum Spotlight is showing promising results as they look for better ways to more easily and quickly diagnose Musculoskeletal disease," said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. "The group has demonstrated how FT-IR can be used to benefit biomedical research and to help development of new diagnostic techniques, and PerkinElmer has demonstrated how its analytical tools can be applied across new functions and disciplines."
For additional information about Spectrum Spotlight FT-IR systems and their use in bio-imaging, visit www.perkinelmer.com/spotlight.
About the Biophysics of Bone and Cartilage Group
The BBC group at the University of Kuopio applies quantitative physical techniques for the characterization of normal cartilage and bone structure and properties. It also focuses on the development of new physical techniques for the sensitive diagnostics of osteoarthrosis (OA) and osteoporosis, the most challenging diseases of our musculoskeletal system. Experimental methods include mechanical, acoustic (ultrasound), magnetic resonance (MR) and quantitative microscopic techniques, applied for in vitro, in situ and/or in vivo studies. Analytic and computational (finite element analysis) techniques are used to model experimental findings. For more information, visit www.luotain.uku.fi.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to cyclical downturns affecting several of the industries into which we sell our products, our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, risks related to our international operations, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recently filed annual report on Form 10-K and in our most recently filed quarterly report on Form 10-Q. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Spectrum is a trademark and PerkinElmer is a registered trademark of PerkinElmer, Inc.
Litref D-6598